HUP0001237A2 - Módszerek érrendszeri rendellenességek gyógykezeléséhez - Google Patents
Módszerek érrendszeri rendellenességek gyógykezeléséhezInfo
- Publication number
- HUP0001237A2 HUP0001237A2 HU0001237A HUP0001237A HUP0001237A2 HU P0001237 A2 HUP0001237 A2 HU P0001237A2 HU 0001237 A HU0001237 A HU 0001237A HU P0001237 A HUP0001237 A HU P0001237A HU P0001237 A2 HUP0001237 A2 HU P0001237A2
- Authority
- HU
- Hungary
- Prior art keywords
- methods
- vascular disorders
- treating vascular
- apc
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 208000019553 vascular disease Diseases 0.000 title 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 101800004937 Protein C Proteins 0.000 abstract 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 abstract 1
- 101800001700 Saposin-D Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960000856 protein c Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4866—Protein C (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Surgery (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Atalálmány tárgyát egy, az érelzáródással és artériástrőmbűsembóliával kapcsőlatős rendellenességekben szenvedő hűmánpáciensek számára kidőlgőzőtt gyógykezelési módszer képezi, melyneksőrán az említett páciensnél aktivált prőtein C 0,01-0,05mg/kg/órásadagja kerül beadásra. Atalálmány tárgyát képezi tővábbá egy egyszeriadagős, 5-20mg aktivált prőtein C-t tartalmazó fiőla, valamint azaktivált prőtein C 0,01-0,05mg/kg/órás dózisban gyógyszerként történőalkalmazása az érelzáródással és artériás trőmbűsembóliávalkapcsőlatős rendellenességek gyógykezelésében. ŕ
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6254997P | 1997-10-20 | 1997-10-20 | |
US6476597P | 1997-11-07 | 1997-11-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0001237A2 true HUP0001237A2 (hu) | 2000-08-28 |
HUP0001237A3 HUP0001237A3 (en) | 2002-01-28 |
Family
ID=26742406
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0001237A HUP0001237A3 (en) | 1997-10-20 | 1998-03-24 | Methods for treating vascular disorders |
HU0100025A HU224901B1 (en) | 1997-10-20 | 1998-10-14 | Methods for treating hypercoagulable states or acquired protein c deficiency |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0100025A HU224901B1 (en) | 1997-10-20 | 1998-10-14 | Methods for treating hypercoagulable states or acquired protein c deficiency |
Country Status (28)
Country | Link |
---|---|
US (7) | US6037322A (hu) |
EP (2) | EP0913156B1 (hu) |
JP (2) | JP3805981B2 (hu) |
KR (1) | KR100798174B1 (hu) |
CN (1) | CN1276726A (hu) |
AT (1) | ATE292979T1 (hu) |
AU (1) | AU748417B2 (hu) |
BR (1) | BR9812965A (hu) |
CA (1) | CA2306983A1 (hu) |
DE (1) | DE69829721T2 (hu) |
DK (1) | DK0913156T3 (hu) |
EA (1) | EA002496B1 (hu) |
ES (1) | ES2239382T3 (hu) |
HK (1) | HK1020529A1 (hu) |
HU (2) | HUP0001237A3 (hu) |
ID (1) | ID24901A (hu) |
IL (2) | IL135712A0 (hu) |
MY (1) | MY117655A (hu) |
NO (1) | NO20002005L (hu) |
NZ (1) | NZ504026A (hu) |
PL (1) | PL200515B1 (hu) |
PT (1) | PT913156E (hu) |
SI (1) | SI0913156T1 (hu) |
TR (1) | TR200001059T2 (hu) |
TW (1) | TWI225404B (hu) |
UA (1) | UA72194C2 (hu) |
WO (1) | WO1999020293A1 (hu) |
ZA (1) | ZA989385B (hu) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6630137B1 (en) | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
HU224826B1 (en) | 1997-04-28 | 2006-02-28 | Lilly Co Eli | Activated protein c formulations |
HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
US6844315B2 (en) * | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
US6921751B1 (en) * | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
US20040202645A1 (en) * | 2003-04-08 | 2004-10-14 | Khan Nisar Ahmed | Administration of gene-regulatory peptides |
US20030220258A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US7175679B2 (en) * | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
EP1138692A1 (en) | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
US20050227925A1 (en) * | 2004-04-08 | 2005-10-13 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
US8680059B2 (en) | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
US6287516B1 (en) | 1998-07-10 | 2001-09-11 | Immunocept, L.L.C. | Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease |
US20040199099A1 (en) * | 1998-07-10 | 2004-10-07 | Matson James R | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
CN1324244A (zh) | 1998-10-22 | 2001-11-28 | 伊莱利利公司 | 治疗脓毒症的方法 |
CA2351067A1 (en) * | 1998-11-13 | 2000-05-25 | Eli Lilly And Company | Method of treating heparin-induced thrombocytopenia |
BR9915572A (pt) * | 1998-11-23 | 2001-08-14 | Lilly Co Eli | Processo de tratamento de doença de célula falciforme e talassemia |
WO2001056532A2 (en) * | 2000-02-04 | 2001-08-09 | The Scripps Research Institute | Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
US6736972B1 (en) | 2000-03-24 | 2004-05-18 | Immunocept, L.L.C. | Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases |
US8535258B2 (en) * | 2000-03-24 | 2013-09-17 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
US7291122B2 (en) * | 2000-03-24 | 2007-11-06 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
US7204981B2 (en) * | 2000-03-28 | 2007-04-17 | Eli Lilly And Company | Methods of treating diseases with activated protein C |
DE60111620T2 (de) * | 2000-03-28 | 2006-05-18 | Eli Lilly And Co., Indianapolis | Aktiviertes protein c zur behandlung von pankreatitis |
USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
US7576174B2 (en) * | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
US7358330B2 (en) | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
US20050037430A1 (en) * | 2000-03-29 | 2005-02-17 | Biotempt B.V. | Methods and uses for protein breakdown products |
EP1300418A1 (en) | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
US6787040B2 (en) * | 2000-05-16 | 2004-09-07 | Immunocept, L.L.C. | Method and system for colloid exchange therapy |
US8597516B2 (en) * | 2000-05-16 | 2013-12-03 | Immunocept, L.L.C. | Methods and systems for colloid exchange therapy |
US7087578B2 (en) * | 2000-05-24 | 2006-08-08 | Eli Lilly And Company | Formulations and methods for treating hypercoagulable states |
WO2002024215A2 (en) * | 2000-09-18 | 2002-03-28 | Eli Lilly And Company | Method for using activated protein c for the treatment of coagulation-associated disorders |
CN100404673C (zh) | 2001-02-19 | 2008-07-23 | 默克专利有限公司 | 鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途 |
US20040198652A1 (en) * | 2001-04-24 | 2004-10-07 | Carter J. Paul | Methods and compositions for preventing and treating septic shock and endotoxemia |
WO2002100445A1 (en) * | 2001-06-13 | 2002-12-19 | The University Of Sydney | Treatment and composition for wound healing |
US20030055003A1 (en) * | 2001-07-19 | 2003-03-20 | David Bar-Or | Use of copper chelators to inhibit the inactivation of protein C |
US20030220259A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of neurological disorders |
PL372138A1 (en) | 2001-10-15 | 2005-07-11 | Chiron Corporation | Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
US20040013661A1 (en) * | 2001-12-21 | 2004-01-22 | Gert Wensvoort | Stratification |
US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
US7501391B2 (en) * | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
US7786084B2 (en) | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
US7560433B2 (en) * | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
US20030220260A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Peptide compositions |
AU2003213146A1 (en) * | 2002-03-08 | 2003-09-22 | Eli Lilly And Company | Activated protein c formulations |
TW200407335A (en) * | 2002-07-22 | 2004-05-16 | Chugai Pharmaceutical Co Ltd | Non-neutralizing antibody to inhibit the inactivation of activated protein C |
WO2004014315A2 (en) * | 2002-08-13 | 2004-02-19 | Arbios Systems, Inc. | Selective plasma exchange therapy |
WO2004056309A2 (en) | 2002-12-05 | 2004-07-08 | Socratech L.L.C. | Neuroprotective activity of activated protein c is independent of its anticoagulant activity |
WO2004065418A1 (ja) * | 2003-01-20 | 2004-08-05 | Chugai Seiyaku Kabushiki Kaisha | 抗pci中和抗体 |
US20070142272A1 (en) * | 2003-01-24 | 2007-06-21 | Zlokovic Berislav V | Neuroprotective activity of activated protein c independent of its anticoagulant activity |
US7517529B2 (en) * | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
AU2004241069B2 (en) | 2003-05-15 | 2010-09-09 | Genentech, Inc. | Methods and compositions for the prevention and treatment of sepsis |
US9192657B2 (en) * | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
KR101284884B1 (ko) | 2003-07-08 | 2013-07-10 | 더 스크립스 리서치 인스티튜트 | 정상의 세포보호 활성 및 저하된 항응고 활성을 지닌활성화 단백질 c 변이체 |
US20090227669A1 (en) * | 2004-01-23 | 2009-09-10 | The University Of Toledo | Compositions and Methods for Perioperative Bladder Instillation |
RU2006136267A (ru) * | 2004-03-17 | 2008-04-27 | Чирон Корпорейшн (Us) | Лечение тяжелой внебольничной пневмонии путем введения ингибитора пути тканевого фактора (tfpi) |
EP1745145A4 (en) * | 2004-05-11 | 2008-03-26 | Heptest Lab Inc | COMPOSITIONS, KIT AND METHOD IN ONE STEP FOR MONITORING COMPOUNDS HAVING XA AND / OR ANTIFACTOR IIA ANTIFACTOR ACTIVITIES |
WO2006014839A2 (en) * | 2004-07-23 | 2006-02-09 | The University Of Rochester | Activated protein c inhibits undesirable effects of plasminogen activator in the brain |
WO2006124770A2 (en) * | 2005-05-13 | 2006-11-23 | The Feinstein Institute For Medical Research | Treatment of sepsis and inflammation with alpha2a adrenergic antagonists |
CN101262879B (zh) * | 2005-06-24 | 2013-04-10 | 德拉格雷丘尔公司 | 在影响呼吸道的炎症病状中气道施用活化的蛋白c |
JP4846799B2 (ja) | 2005-07-05 | 2011-12-28 | バイオテンプト ベー.フェー. | 腫瘍の治療 |
EP1864692A1 (en) | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
US7785857B2 (en) * | 2006-08-31 | 2010-08-31 | Saint Louis University | Protein C variant |
GR1005700B (el) * | 2006-09-01 | 2007-10-22 | (40%) ����� �������� | Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα |
US20100284997A1 (en) * | 2006-10-31 | 2010-11-11 | Griffin John H | Dosing regimen of activated protein c and variants having reduced anticoagulant activity |
RU2445365C1 (ru) * | 2010-11-03 | 2012-03-20 | Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") | Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты) |
RU2490722C1 (ru) * | 2012-04-24 | 2013-08-20 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | Способ восстановления кровотока в регионе тромбированной вены в эксперименте |
US20150150954A1 (en) | 2012-07-04 | 2015-06-04 | The University Of Sydney | Treatment of inflammatory skin disorders |
DK3137102T3 (da) | 2014-04-16 | 2021-10-11 | Zz Biotech Llc | Apc til anvendelse til behandling af unormal kutan ardannelse |
EP3807427A1 (en) | 2018-06-15 | 2021-04-21 | AB Sandvik Materials Technology | A duplex stainless steel strip and method for producing thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
US5516650A (en) * | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
US5084274A (en) * | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
US4992373A (en) * | 1987-12-04 | 1991-02-12 | Eli Lilly And Company | Vectors and compounds for direct expression of activated human protein C |
US5009889A (en) * | 1987-12-31 | 1991-04-23 | Oklahoma Medical Research Foundation | Treatment of dysfunctional vascular endothelium using activated protein C |
GB8819607D0 (en) * | 1988-08-17 | 1988-09-21 | Wellcome Found | Novel combination |
US4981952A (en) * | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
US5254532A (en) * | 1989-06-26 | 1993-10-19 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same |
IL97312A (en) * | 1990-02-23 | 1999-01-26 | Lilly Co Eli | A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient |
AT402262B (de) * | 1991-06-20 | 1997-03-25 | Immuno Ag | Arzneimittel enthaltend aktiviertes protein c |
MY110664A (en) * | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
JP3434326B2 (ja) * | 1992-08-25 | 2003-08-04 | 財団法人化学及血清療法研究所 | 成人呼吸窮迫症候群(ards)予防、治療剤 |
JP2825739B2 (ja) * | 1993-09-20 | 1998-11-18 | 帝人株式会社 | 急性肝不全治療剤 |
JP3802104B2 (ja) * | 1995-05-31 | 2006-07-26 | 財団法人化学及血清療法研究所 | 脊髄損傷に伴う神経障害の予防・治療剤 |
WO1997020043A1 (en) * | 1995-11-30 | 1997-06-05 | Zymogenetics, Inc. | Protein c production in transgenic animals |
HU224826B1 (en) * | 1997-04-28 | 2006-02-28 | Lilly Co Eli | Activated protein c formulations |
HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
-
1998
- 1998-03-24 HU HU0001237A patent/HUP0001237A3/hu unknown
- 1998-09-28 US US09/161,900 patent/US6037322A/en not_active Expired - Lifetime
- 1998-10-14 CA CA002306983A patent/CA2306983A1/en not_active Abandoned
- 1998-10-14 TW TW087117061A patent/TWI225404B/zh not_active IP Right Cessation
- 1998-10-14 KR KR1020007004170A patent/KR100798174B1/ko not_active IP Right Cessation
- 1998-10-14 HU HU0100025A patent/HU224901B1/hu not_active IP Right Cessation
- 1998-10-14 CN CN98810307A patent/CN1276726A/zh active Pending
- 1998-10-14 UA UA2000042259A patent/UA72194C2/uk unknown
- 1998-10-14 ID IDW20000683A patent/ID24901A/id unknown
- 1998-10-14 JP JP2000516690A patent/JP3805981B2/ja not_active Expired - Fee Related
- 1998-10-14 EA EA200000445A patent/EA002496B1/ru not_active IP Right Cessation
- 1998-10-14 WO PCT/US1998/021723 patent/WO1999020293A1/en not_active Application Discontinuation
- 1998-10-14 IL IL13571298A patent/IL135712A0/xx unknown
- 1998-10-14 AU AU98040/98A patent/AU748417B2/en not_active Ceased
- 1998-10-14 TR TR2000/01059T patent/TR200001059T2/xx unknown
- 1998-10-14 ZA ZA9809385A patent/ZA989385B/xx unknown
- 1998-10-14 BR BR9812965-1A patent/BR9812965A/pt not_active Application Discontinuation
- 1998-10-14 NZ NZ504026A patent/NZ504026A/xx not_active IP Right Cessation
- 1998-10-14 PL PL340096A patent/PL200515B1/pl not_active IP Right Cessation
- 1998-10-15 EP EP98308413A patent/EP0913156B1/en not_active Expired - Lifetime
- 1998-10-15 EP EP04005955A patent/EP1449537A3/en not_active Withdrawn
- 1998-10-15 PT PT98308413T patent/PT913156E/pt unknown
- 1998-10-15 DE DE69829721T patent/DE69829721T2/de not_active Expired - Lifetime
- 1998-10-15 ES ES98308413T patent/ES2239382T3/es not_active Expired - Lifetime
- 1998-10-15 MY MYPI98004703A patent/MY117655A/en unknown
- 1998-10-15 DK DK98308413T patent/DK0913156T3/da active
- 1998-10-15 AT AT98308413T patent/ATE292979T1/de active
- 1998-10-15 SI SI9830773T patent/SI0913156T1/xx unknown
- 1998-10-16 US US09/174,507 patent/US6008199A/en not_active Expired - Lifetime
-
1999
- 1999-10-08 US US09/415,761 patent/US6268344B1/en not_active Expired - Fee Related
- 1999-10-08 US US09/415,876 patent/US6156734A/en not_active Expired - Lifetime
- 1999-11-02 HK HK99104976A patent/HK1020529A1/xx not_active IP Right Cessation
- 1999-12-16 US US09/465,076 patent/US6268337B1/en not_active Expired - Fee Related
-
2000
- 2000-04-17 NO NO20002005A patent/NO20002005L/no not_active Application Discontinuation
- 2000-04-17 IL IL135712A patent/IL135712A/en not_active IP Right Cessation
- 2000-05-10 US US09/568,146 patent/US6489296B1/en not_active Expired - Fee Related
-
2001
- 2001-06-08 US US09/877,759 patent/US6426071B2/en not_active Expired - Fee Related
-
2004
- 2004-11-11 JP JP2004327938A patent/JP2005097313A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0001237A2 (hu) | Módszerek érrendszeri rendellenességek gyógykezeléséhez | |
WO1997036609A3 (en) | Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest | |
HU9301978D0 (en) | Application of complementary inhibitors in medical preparatives used for treatment of inflammatory diseases of intestines and skin | |
WO2000021548A3 (en) | Angiogenically effective unit dose of fgf and method of administering | |
PL338982A1 (en) | Drug for improving duration of muscle action or for treating muscular disorders or diseases | |
AU693833B2 (en) | Products containing G-CSF and TNF binding protein | |
HK1075409A1 (en) | Angiogenically effective unit dose of fgf-2 and method of use fgf-2 | |
CA2156481A1 (en) | 5-ht2 receptor antagonist compositions useful in treating venous conditions | |
EP1304108A3 (en) | Anti-arrhythmic composition and methods of treatment | |
MY105798A (en) | Treatment of leukocyte dysfunction with gm-csf. | |
WO2002058720A3 (en) | Angiogenically effective unit dose of fgf-2 and method of use | |
HUP0003256A2 (hu) | Pentozán-poliszulfát és sói alkalmazása krónikus progresszív érhegesedéssel járó betegségek kezelésére alkalmas gyógyszerkészítmények előállítására | |
ID23176A (id) | Metoda untuk mengobati gangguan pembuluh darah | |
NZ307601A (en) | Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions | |
WO2001041771A3 (de) | Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne | |
SE9101341D0 (sv) | New medicinal use | |
RU95102346A (ru) | Способ лечения дисциркуляторной энцефалопатии | |
RU94004116A (ru) | Способ лечения розовых угрей | |
RU97110054A (ru) | Способ лечения синдрома "диабетическая стопа" | |
RU96107031A (ru) | Способ лечения хореи гентингтона | |
UA19596A (uk) | Спосіб лікуваhhя гіпертоhічhої хвороби гірудорефлексотерапією | |
RU98102790A (ru) | Способ лечения нейроваскулярных заболеваний глаза |